Clinical Trials
33 trialsCASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
Masonic Cancer Center, University of Minnesota
PREDICT
Alliance for Clinical Trials in Oncology
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
Dana-Farber Cancer Institute
CHAMP
Duke University
Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
M.D. Anderson Cancer Center
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC
M.D. Anderson Cancer Center
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
University of Washington
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
M.D. Anderson Cancer Center
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Jonsson Comprehensive Cancer Center
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
CATCH-177
Case Comprehensive Cancer Center
PKUFH-GS5
Peking University First Hospital
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Icahn School of Medicine at Mount Sinai
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway
University of Washington
Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
University of Washington
Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
Seattle Institute for Biomedical and Clinical Research
Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel
Barbara Ann Karmanos Cancer Institute
Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Jonsson Comprehensive Cancer Center
Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer
M.D. Anderson Cancer Center
PRO-PLAT
Cantonal Hospital of St. Gallen
Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer
Weill Medical College of Cornell University
Calcitriol and Carboplatin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
OHSU Knight Cancer Institute
Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
Alliance for Clinical Trials in Oncology
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
Alliance for Clinical Trials in Oncology
Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer
Memorial Sloan Kettering Cancer Center
Carboplatin-Etoposide Combination in Hormone-Resistant Prostate Cancers
Centre Leon Berard
Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma
SCRI Development Innovations, LLC
A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer
Dana-Farber Cancer Institute